BDR Pharmaceuticals Sues FDA Over Phathom's Drug Exclusivity
What happened
BDR Pharmaceuticals filed a lawsuit against the U.S. Food and Drug Administration and related Federal Defendants in the United States District Court for the District of Columbia. The suit primarily challenges the FDA's refusal to accept an abbreviated new drug application (ANDA) referencing Phathom Pharmaceuticals' new drug application (NDA) for VOQUEZNA®. BDR alleges that the FDA improperly used the GAIN Act to extend Phathom's New Chemical Entity (NCE) exclusivity for VOQUEZNA tablets. Phathom Pharmaceuticals stated that the FDA correctly evaluated this matter in its June 6, 2025 grant of Phathom’s December 11, 2024 Citizen Petition, which granted 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032.
From manilatimes.net
Why it matters
This legal challenge concerns the regulatory protection of a pharmaceutical product. The outcome could affect the duration of market exclusivity for VOQUEZNA tablets. If BDR's claims are upheld, it could impact the commercialization timeline and revenue streams for Phathom Pharmaceuticals.
From manilatimes.net
Who's involved
- FDAThe regulatory agency being sued over its drug application decisions.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- FDASpeculative
Phathom Pharmaceuticals might see its revenue streams affected depending on the court's ruling on the drug's exclusivity period.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Drug exclusivity lawsuit may force Congress to review FDA mandatesLegal challenge to drug exclusivity may prompt legislative review of FDA mandatesPossible
- How could the BDR lawsuit challenging FDA decisions affect the Department of Health & Human Services?Legal challenge to FDA exclusivity decisions increases oversight demands on HHSPossible
- BDR lawsuit could accelerate generic drug approvals at CDERBDR's lawsuit may force CDER to accelerate generic drug approvalsPossible
Keep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.
- Litigation regarding FDA approval process.
- Belite Bio, Inc. is seeking priority review for a drug application from the FDA and disclosed stock sales via SEC filing.